Mr. Truex currently serves as the Executive Chairman of the Board. He served as Director and Chief Executive Officer since the inception of Anthera in 2004 through 2016. He was responsible for negotiating Anthera’s product licenses for both blisibimod, our anti-BAFF peptibody program from Amgen, and recently, Sollpura™(liprotamase), a novel enzyme replacement product, from Eli Lilly and Company. During his career Mr. Truex has been involved with over $500 million in private, public and debt financings and over $1 billion in various strategic in-licensing, out-licensing and merger/acquisition transactions including initial public offerings for Trius Therapeutics (Board Member, 2010), Anthera (CEO, 2010), Peninsula Pharmaceuticals (2004), and Versicor (Vice President, 2000).
Prior to founding Anthera Pharmaceuticals, Mr. Truex served as a Founder, Director, President and CEO of Peninsula Pharmaceuticals. During that time Mr. Truex negotiated both of Peninsula’s product agreements with Shionogi & Co., Ltd. (Doribax®, doripenem) and Takeda Chemical Industries (Teflaro®, ceftaroline). Peninsula was acquired by Johnson and Johnson for $245 million in an all cash transaction. The remaining entity, Cerexa was subsequently acquired in $480 million in cash.
Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Versicor Incorporated (acquired by Pfizer) where he directed early commercial efforts for their infectious disease portfolio and participated in the company’s successful $55 million initial public offering.
Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos®’ Evista®’ and Humalog 75/25®). His business development experience includes the Lilly ICOS LLC joint venture for the development of Cialis® and two major product divestitures (anidulafungin, Eraxis® and loracarbef, Lorabid®), and numerous research collaborations.
Mr. Truex obtained his Masters of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo. Mr. Truex sits on the Indiana University West Coast Advisory Board for the Johnson Center of Entrepreneurship and Innovation, is a member of the Board of Directors of Milestone Pharmaceuticals Limited (Chairman) and involved as an advisor to a number of early stage ventures in multiple industries. His past board appointments include Peninsula Pharmaceuticals, Trius Therapeutics, and Protagonist Therapeutics.